Apr 16, 2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and i...
Apr 4, 2019
RESEARCH TRIANGLE PARK, NC, April 04, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that its Board of Directors has appointed Nancy R. Phelan...
Apr 3, 2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Moderna’s Chief Medical Offic...
Mar 4, 2019
RESEARCH TRIANGLE PARK, NC and NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Adhera Therapeutics (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, and Alyvant, a company focused on tech-enabled pharma commercializati...
Feb 6, 2019
Over 200 prescribers have written at least one prescription for PRESTALIA and over 600 patients are taking the medication PRESTALIA was launched in Q3 2018, powered by the Company's proprietary DyrctAxess platform
Nov 20, 2018
Research Triangle Park, NC, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), an emerging specialty pharmaceutical company commercializing therapies that leverage its innovative distribution model and technology to improve the quality of care for patients suffering from ch...